Literature DB >> 29787843

Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials.

Alexandra B Kimball1, Murali Sundaram2, Alan L Shields3, Stacie Hudgens4, Martin Okun5, Catherine Foley3, Arijit Ganguli2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29787843     DOI： 10.1016/j.jaad.2018.05.015

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  5 in total

1.  Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review.

Authors:  Asma Amir Ali; Elizabeth K Seng; Afsaneh Alavi; Michelle A Lowes
Journal:  J Am Acad Dermatol       Date:  2019-05-29       Impact factor: 11.527

Review 2.  Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis.

Authors:  Aikaterini Tsentemeidou; Elena Sotiriou; Nikolaos Sideris; Alexandra Kourouklidou; Aimilios Lallas; Dimitrios Ioannides; Efstratios Vakirlis
Journal:  Dermatol Pract Concept       Date:  2022-04-01

3.  Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience.

Authors:  Andrea Chiricozzi; Giulia Giovanardi; Simone Garcovich; Dalma Malvaso; Giacomo Caldarola; Barbara Fossati; Cristina Guerriero; Clara De Simone; Ketty Peris
Journal:  Acta Derm Venereol       Date:  2020-06-11       Impact factor: 3.875

Review 4.  Systematic review of immunomodulatory therapies for hidradenitis suppurativa.

Authors:  Shi Yu Derek Lim; Hazel H Oon
Journal:  Biologics       Date:  2019-05-13

Review 5.  TNF-α inhibitors in the treatment of hidradenitis suppurativa.

Authors:  Kevin T Savage; Kelsey S Flood; Martina L Porter; Alexa B Kimball
Journal:  Ther Adv Chronic Dis       Date:  2019-05-27       Impact factor: 5.091
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.